Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Genmab ( (GMAB) ).
On May 12, 2026, Genmab A/S announced a minor capital increase of 2,346 shares following the exercise of employee warrants, raising about DKK 3.0 million and diluting existing shareholders by roughly 0.004%. The new ordinary shares, each with a nominal value of DKK 1 and full voting and dividend rights upon subscription, will be listed on Nasdaq Copenhagen once registered, bringing Genmab’s total share capital to DKK 62,353,067 distributed across an equal number of shares.
The most recent analyst rating on (GMAB) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Neutral.
The score is supported by strong financial performance (rapid growth, high margins, solid cash generation) and a constructive earnings outlook with meaningful pipeline catalysts, but is held back by the sharp 2025 leverage increase and weaker earnings quality signals, plus bearish near-term technical momentum despite oversold readings.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab A/S is an international biotechnology company focused on developing innovative antibody medicines for cancer and other serious diseases. Founded in 1999 and headquartered in Copenhagen, it has built a broad portfolio of antibody-based formats, including bispecific antibodies, antibody-drug conjugates and immune-modulating therapies, and powers eight approved medicines while advancing a strong late-stage clinical pipeline.
Average Trading Volume: 1,769,548
Technical Sentiment Signal: Sell
Current Market Cap: $15.43B
Learn more about GMAB stock on TipRanks’ Stock Analysis page.